A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

NCT02352558 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Malignancy

Interventions

DRUG: BBI608
DRUG: Dexamethasone
DRUG: Bortezomib
DRUG: Imatinib
DRUG: Ibrutinib

Sponsor

Sumitomo Pharma America, Inc.